Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 92 for:    Primary Sclerosing Cholangitis

A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis (BUTEO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02239211
Recruitment Status : Completed
First Posted : September 12, 2014
Last Update Posted : May 3, 2019
Sponsor:
Collaborators:
Biotie Therapies Corp.
University Hospital Birmingham
National Institute for Health Research, United Kingdom
Information provided by (Responsible Party):
University of Birmingham

Brief Summary:
This is a phase II study to determine the safety and preliminary efficacy of a human monoclonal antibody (BTT1023) which targets the vascular adhesion protein (VAP-1) and its use in the treatment of patients with primary sclerosing cholangitis (PSC).

Condition or disease Intervention/treatment Phase
Primary Sclerosing Cholangitis Drug: BTT1023 Phase 2

Detailed Description:

Primary sclerosing cholangitis is a progressive immune mediated biliary disease characterised by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis. For patients with elevated alkaline phosphatase (ALP) in particular, progressive disease is predicted, that currently results in a need for liver transplantation in the majority. No current medical therapy has as yet been shown to be effective in altering the natural history of disease. For this reason patients with PSC with elevated ALP values will be recruited to this study, to evaluate the impact of Vap-1 blockade by BTT1023, in an early phase study focused on biochemical efficacy and safety.

This is an early phase study of BTT1023 in immune mediated liver disease, with the rationale to identify biochemical efficacy of effect (reduction in ALP) and safety, in an orphan disease indication for PSC that presently lacks any other medical therapy. The study design therefore focuses on identifying early biochemical efficacy signals to justify larger scale, randomised controlled studies over longer duration.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).
Actual Study Start Date : September 8, 2015
Actual Primary Completion Date : October 23, 2018
Actual Study Completion Date : October 23, 2018


Arm Intervention/treatment
Experimental: BTT1023
BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
Drug: BTT1023
IV (in the vein) Investigational Medicinal Product (IMP)




Primary Outcome Measures :
  1. Response at Visit 10 (Day 99): a reduction in serum ALP by 25% or more from baseline to Visit 10 (Day 99) [ Time Frame: 99 days ]

Secondary Outcome Measures :
  1. Treatment Compliance (including patient withdrawal) [ Time Frame: 120 days ]
    These will be measured to evaluate the tolerability of BTT1203 in patients with PSC

  2. Serious Adverse Event (SAE) frequency [ Time Frame: 120 days ]
    These will be measured to evaluate the safety, effective dose, and tolerability of BTT1203 in patients with PSC

  3. Adverse Event (AE) frequency [ Time Frame: 120 days ]
    These will be measured to evaluate the safety, effective dose, and tolerability of BTT1203 in patients with PSC

  4. Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire EQ-5D [ Time Frame: 99 days ]
    Using validated EQ-5D scoring system

  5. Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire Fatigue Severity Scale [ Time Frame: 99 days ]
    The scoring is done by calculating the average response to the questions (adding up all the answers and dividing by nine).

  6. Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire Pruritus Visual Analogue Score [ Time Frame: 99 days ]
    VAS measured as per guidelines

  7. Calculation of any change (improvement or worsening) from baseline to Day 99 in Inflammatory Bowel Disease Diaries (if applicable) [ Time Frame: 99 days ]
  8. Calculation of any change (improvement or worsening) from baseline to Day 99 in enhanced liver fibrosis test [ Time Frame: 99 days ]
  9. Calculation of any change (improvement or worsening) from baseline to Day 99 in Fibroscan measures [ Time Frame: 99 days ]
  10. Calculation of any change (improvement or worsening) from baseline to Day 99 in Aspartate Transaminase (AST) [ Time Frame: 99 days ]
  11. Calculation of any change (improvement or worsening) from baseline to Day 99 in Alanine Transaminase (ALT) [ Time Frame: 99 days ]
  12. Calculation of any change (improvement or worsening) from baseline to Day 99 in Alkaline Phosphatase (ALP) [ Time Frame: 99 days ]
  13. Calculation of any change (improvement or worsening) from baseline to Day 99 in Gamma Glutamyl Transferase (GGT) [ Time Frame: 99 days ]
  14. Calculation of any change (improvement or worsening) from baseline to Day 99 in Bilirubin [ Time Frame: 99 days ]
  15. Calculation of any change (improvement or worsening) from baseline to Day 99 in Albumin [ Time Frame: 99 days ]
  16. Calculation of any change (improvement or worsening) from baseline to Day 99 in International Normalised Ratio (INR) [ Time Frame: 99 days ]
  17. Calculation of any change (improvement or worsening) from baseline to Day 99 in Mayo PSC Risk Score [ Time Frame: 99 days ]
    PSC Risk score calculated as per The Revised Natural History Model for Primary Sclerosing Cholangitis

  18. Calculation of any change (improvement or worsening) from baseline to Day 99 in Model for End Stage Liver Disease (MELD) Score [ Time Frame: 99 days ]
    MELD calculated as per pre 2016 guidelines

  19. Evaluate changes (improvement or worsening) in sVAP-1/SSAO as a biomarker of liver disease activity across the trial period [ Time Frame: 120 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females 18 - 75 years of age who are willing and able to provide informed, written consent and comply with all trial requirements
  2. Clinical diagnosis of PSC as evident by chronic cholestasis of more than six months duration with either a consistent MRI showing sclerosing cholangitis or a liver biopsy consistent with PSC in the absence of a documented alternative aetiology for sclerosing cholangitis
  3. In those with concomitant Inflammatory Bowel Disease, clinical and colonoscopic evidence, (in line with the patient's standard of care; within 18 months) of stable disease, without findings of high grade dysplasia
  4. In those on treatment with UDCA, therapy must be stable for at least 3 months, and at a dose not greater than 20 mg/kg/day. In those not on treatment with UDCA at the time of screening, a minimum of 8 weeks since the last dose of UDCA should be recorded
  5. Serum ALP greater than 1.5 x ULN
  6. Stable serum ALP levels (levels must not change by more than 25% from Screening Visit 1 and Screening Visit 2)
  7. Female subjects of childbearing potential must have a negative pregnancy test prior to starting trial treatment. For the purposes of this trial, a female subject of childbearing potential is a woman who has not had a hysterectomy, bilateral oophorectomy, or medically-documented ovarian failure. Women ≤ 50 years of age with amenorrhea of any duration will be considered to be of childbearing potential
  8. All sexually active women of childbearing potential must agree to use two forms of highly effective method of contraception from the Screening Visit throughout the trial period and for 99 days following the last dose of trial drug. If using hormonal agents the same method must have been used for at least 1 month before trial dosing and subjects must use a barrier method as the other form of contraception. Lactating women must agree to discontinue breast feeding before trial investigational medicinal product administration
  9. Men, if not vasectomised, must agree to use barrier contraception (condom plus spermicide) during heterosexual intercourse from screening through to trial completion and for 99 days from the last dose of trial investigational medicinal product
  10. Patients must weigh ≥ 40 kg

Exclusion Criteria:

  1. Presence of documented secondary sclerosing cholangitis on prior clinical investigations
  2. Presence of alternative causes of liver disease, that are considered by the Investigator to be the predominant active liver injury at the time of screening, including viral hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis. Patients with possible overlap syndrome with autoimmune hepatitis are excluded if the Investigator considers autoimmune hepatitis as the predominant liver injury
  3. AST and ALT >10 x ULN or bilirubin >3 x ULN or INR >1.3 in the absence of anti-coagulants
  4. Serum creatinine >130μmol/L or platelet count <50 x 109/L
  5. Any evidence of hepatic decompensation past or present, including ascites, episodes of hepatic encephalopathy or variceal bleeding
  6. Recent cholangitis within last 90 days or ongoing need for prophylactic antibiotics
  7. Pregnancy or breast feeding
  8. Harmful alcohol consumption as evaluated by the Investigator
  9. Flare in colitis activity within last 90 days requiring intensification of therapy beyond baseline maintenance treatment; use of oral prednisolone >10 mg/day, biologics (i.e. monoclonal antibodies) and or hospitalisation for colitis within 90 days. Prior use of biologics is not a contraindication to screening
  10. Diagnosed cholangiocarcinoma or high clinical suspicion of cholangiocarcinoma either clinically or by imaging
  11. Concurrent malignancies or invasive cancers diagnosed within past 3 years except for adequately treated basal cell and squamous cell carcinoma of the skin and in situ carcinoma of the uterine cervix
  12. Presence of a percutaneous drain or bile duct stent
  13. Major surgical procedure within 30 days of screening
  14. Prior organ transplantation
  15. Known hypersensitivity to the investigational product or any of its formulation excipients
  16. Unavailable for follow-up assessment or concern for subject's compliance
  17. Participation in an investigational trial of a drug or device within 60 days of screening or 5 half lives of the last dose of investigational drug, where the trial drug half-life is greater than 12 days
  18. Any other condition that in the opinion of the Investigator renders the subject a poor risk for inclusion into the trial
  19. Positive screening test for tuberculosis (TB) (including T-SPOT.TB TB test), unless respiratory review confirms false positive test results
  20. Receipt of live vaccination within 6 weeks prior to Screening Visit 2
  21. Known HIV positive status

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02239211


Locations
Layout table for location information
United Kingdom
Queens Medical Centre
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
University Hospitals Birmingham NHS Foundation Trust
Birmingham, West Midlands, United Kingdom, B15 2TH
Addenbrooke's Hospital
Cambridge, United Kingdom
Royal Free Hospital
London, United Kingdom
Royal Victoria Infirmary
Newcastle, United Kingdom
John Radcliffe Hospital
Oxford, United Kingdom
Sponsors and Collaborators
University of Birmingham
Biotie Therapies Corp.
University Hospital Birmingham
National Institute for Health Research, United Kingdom
Investigators
Layout table for investigator information
Principal Investigator: Philip Newsome, MD University of Birmingham

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Birmingham
ClinicalTrials.gov Identifier: NCT02239211     History of Changes
Other Study ID Numbers: RG_13-027
2014-002393-37 ( EudraCT Number )
First Posted: September 12, 2014    Key Record Dates
Last Update Posted: May 3, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of Birmingham:
BUTEO
Primary sclerosing cholangitis
PSC
VAP-1
BTT1023
Human monoclonal antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangitis
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs